Cholinesterase inhibitor

Medical use

While 4 ChEIs are approved in the US for the treatment of Alzheimer's Disease, only three of these are available commercially. The three available are rivastigmine, donepezil, and galantamine, while tacrine is not. They are generally used to treat Alzheimer's disease and dementia. If a benefit occurs, it is generally during the second or third month after starting.

It is difficult to determine which ChEI has greater efficacy, due to design flaws in head-to-head comparison studies.

Pyridostigmine is used in the treatment of myasthenia gravis.

Neostigmine is used in combination with a muscarinic antagonist to reverse the effects of non-depolarizing muscle relaxants e.g. rocuronium bromide

Cholinesterase inhibitor toxicity

Common side effects of one ChEI include insomnia, nausea and vomiting, accidental injury, headache, dizziness, bradycardia, hypotension, ecchymosis, and sleep disturbance.

Binding affinity

Acetylcholinesterase inhibitors

Donepezil, phenserine, huperzine A, and BW284c51 are selective AChE inhibitors.

Butyrylcholinesterase inhibitor

Tetra (monoisopropyl) pyrophosphoramide (Iso-OMPA) and ethopropazine are selective BChE inhibitors.

AChE and BChE inhibitor

Paraoxon and rivastigmine are both acetylcholinesterase inhibitors and butyrylcholinesterase inhibitors.

In 2015, the United States Food and Drug Administration's Adverse Event Reporting System database compared rivastigmine to the other ChEI drugs donepezil and galantamine found that rivastigmine was associated with a higher frequency of reports of death as an adverse event.

Acetylcholinesterase inhibitors and nicotinic receptor modulator

Galantamine might be less well tolerated than donepezil and rivastigmine.

Chemical weapons

Assassination Attempt

Cholinesterase inhibitors came to a public attention in 2020 when Russian opposition and dissent figure Alexei Navalny was treated in Berlin Charité hospital for poisoning by a Russian-made nerve agent which is known since 2019 as belonging to the Novichok agents subgroup of ChEI.

References

References

1. (2012). "Primer on the Autonomic Nervous System". Elsevier.
2. (2014). "From Molecules to Networks". Elsevier.
3. (2013-04-01). "Acetylcholinesterase Inhibitors: Pharmacology and Toxicology". Bentham Science Publishers Ltd..
4. "Cholinesterase Inhibitors (Medical Use & WMD)". [[Tulane University School of Medicine]].
5. (2013). "Environmental Risks of Insecticides Cholinesterase Inhibitors". [[United States National Library of Medicine]].
6. (2016). "Memory Loss, Alzheimer's Disease, and Dementia". Elsevier.
7. (2018-01-08). "An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine". SAGE Publications.
8. (2016). "The Eye". Elsevier.
9. (2019). "Novichok nerve agents banned by chemical-weapons treaty". Nature.
10. (2018). "Novichok agents: A historical, current, and toxicological perspective". Toxicology Communications.
11. (2009). "WHO Model Formulary 2008". World Health Organization.
12. (2012). "Prescribing information: Aricept". Eisai Inc. and Pfizer Inc..
13. (2015). "Handbook of Toxicology of Chemical Warfare Agents". Elsevier.
14. Hersen, Michel. (2006). "Comprehensive handbook of personality and psychopathology". John Wiley.
15. (2015). "Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada". PLOS ONE.
16. (2 September 2020). "Alexei Navalny was poisoned 'using Novichok' nerve agent, say German government". Telegraph Media Group Limited.